公开(公告)号：US20230212613A1

公开(公告)日：2023-07-06

申请号：US17996733

申请日：2021-05-06

Applicant: CELLECTIS S.A.

Inventor： Ming YANG ,  Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Patrick HONG

IPC: C12N15/90 ,  C07K14/725 ,  C12N9/22 ,  C12N5/0783

CPC classification number: C12N15/907 ,  C07K14/7051 ,  C12N9/22 ,  C12N5/0636 ,  C12N2310/20

Abstract: The present disclosure provides methods for targeted insertion of an exogenous sequence at a genomic locus in a cell, wherein said insertion is induced by a sequence-specific endonuclease that has cleavage activity at said locus, at least 5 hours before the introduction into said cell of a DNA template comprising said exogenous sequence.

公开(公告)号：US20250057952A1

公开(公告)日：2025-02-20

申请号：US18562603

申请日：2022-05-23

Applicant: CELLECTIS S.A.

Inventor： Shipra DAS ,  Julien VALTON ,  Laurent POIROT ,  Philippe DUCHATEAU

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C12N15/90

Abstract: The invention relates to methods of treatment of a solid tumor in a patient in need thereof, comprising administering to the patient: (i) an effective amount of engineered immune cells originating from a donor expressing at their cell surface a Chimeric Antigen Receptor (CAR) directed against Fibroblast Activation Protein (FAP), and (ii) an effective amount of an immunotherapy treatment that elicits an immune response in the patient.

公开(公告)号：US20160273003A1

公开(公告)日：2016-09-22

申请号：US15080232

申请日：2016-03-24

Applicant: Cellectis S.A.

Inventor： Philippe DUCHATEAU ,  Christophe PEREZ ,  Sylvia BRUNEAU ,  Jean-Pierre CABANIOLS ,  Julianne SMITH ,  Agnes GOUBLE

IPC: C12N15/90 ,  C07K14/435 ,  C12N15/86 ,  C12N9/22 ,  A61K38/46 ,  C12N7/00

CPC classification number: C12N15/907 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0337 ,  A61K38/00 ,  A61K38/1709 ,  A61K38/465 ,  A61K48/00 ,  A61K48/0058 ,  C07K14/435 ,  C07K2319/81 ,  C12N7/00 ,  C12N9/22 ,  C12N15/1058 ,  C12N15/8509 ,  C12N15/86 ,  C12N15/90 ,  C12N2730/10143 ,  C12N2799/022 ,  C12N2800/80 ,  C12N2830/002 ,  C12N2830/55 ,  C12N2840/20 ,  C12N2840/44 ,  C12Y301/00 ,  C12Y301/21004

Abstract: A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y in a single polypeptide.

Abstract translation: 单链归巢内切核酸酶，其包含具有登录号pdb 1g9y的氨基酸序列的I-CreI的第一变体和在单个多肽中具有登录号pdb 1g9y的氨基酸序列的I-CreI变体的第二变体。

公开(公告)号：US20230279440A1

公开(公告)日：2023-09-07

申请号：US17996701

申请日：2021-05-06

Applicant: CELLECTIS S.A.

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Patrick HONG ,  Laurent POIROT ,  Brian BUSSER ,  Alex BOYNE

IPC: C12N15/90 ,  C12N15/86

CPC classification number: C12N15/907 ,  C12N15/86 ,  C12N2750/14143 ,  C12N2830/42

Abstract: The present disclosure provides methods to genetically modify cells by insertion of an artificial exon (ArtEx) for delivery of therapeutic proteins in specific cell types and more particularly engineered cells for expression of a transgene into the brain of a patient.

公开(公告)号：US20230279350A1

公开(公告)日：2023-09-07

申请号：US18016972

申请日：2021-07-30

Applicant: CELLECTIS S.A.

Inventor： André CHOULIKA ,  Laurent POIROT ,  Beatriz ARANDA ORGILLES ,  Philippe DUCHATEAU

IPC: C12N5/0783 ,  C07K16/28 ,  A61P35/00

CPC classification number: C12N5/0636 ,  C07K16/2887 ,  C07K16/2896 ,  A61P35/00 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2319/03

Abstract: The present invention concerns new engineered immune cells expressing two CARs directed against two different targets, polynucleotides for preparing said immune cells, pharmaceutical compositions comprising said immune cells, and the use of said immune cells in the treatment of cancers.

公开(公告)号：US20130203840A1

公开(公告)日：2013-08-08

申请号：US13649093

申请日：2012-10-10

Applicant: Cellectis S.A.

Inventor： Sylvain ARNOULD ,  Patrick Chames ,  Philippe DUCHATEAU ,  Jean-Charles EPINAT ,  Emmanuel LACROIX ,  Frederic PAQUES

IPC: A61K48/00 ,  A61K38/17

CPC classification number: C12N15/907 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0337 ,  A61K38/00 ,  A61K38/1709 ,  A61K38/465 ,  A61K48/00 ,  A61K48/0058 ,  C07K14/435 ,  C07K2319/81 ,  C12N7/00 ,  C12N9/22 ,  C12N15/1058 ,  C12N15/8509 ,  C12N15/86 ,  C12N15/90 ,  C12N2730/10143 ,  C12N2799/022 ,  C12N2800/80 ,  C12N2830/002 ,  C12N2830/55 ,  C12N2840/20 ,  C12N2840/44 ,  C12Y301/00 ,  C12Y301/21004

Abstract: A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y in a single polypeptide.

Abstract translation: 单链归巢内切核酸酶，其包含具有登录号pdb 1g9y的氨基酸序列的I-CreI的第一变体和在单个多肽中具有登录号pdb 1g9y的氨基酸序列的I-CreI变体的第二变体。

公开(公告)号：US20230248825A1

公开(公告)日：2023-08-10

申请号：US18005284

申请日：2021-07-23

Applicant: CELLECTIS S.A.

Inventor： Shipra DAS ,  Sumin JO ,  Alexandre JUILLERAT ,  Julien VALTON ,  Laurent POIROT ,  Philippe DUCHATEAU

IPC: A61K39/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C12N5/0783 ,  C12N15/113 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K39/4633 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12N5/0636 ,  A61K39/4611 ,  A61K39/4643 ,  C12N15/1138 ,  A61K39/3955 ,  A61K39/4631 ,  A61P35/00 ,  C12N2800/80 ,  C12N2310/20 ,  C12N2506/11 ,  C12N2501/515 ,  C12N2501/51 ,  C12N2501/2302 ,  A61K2039/5158 ,  C12N2310/531 ,  C12N2310/14

Abstract: The invention relates to therapeutic compositions for allogeneic cellular therapy comprising TCR deficient T-cells, which are genetically engineered to express immune cell engagers, and methods related thereto.